BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)

Reuters02-06

Feb 6 (Reuters) - Priovant:

PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)
PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA

Source text: ID:nGNX6Tw17l

Further company coverage: ROIV.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609950605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609950605","market":"nz","top_or_hot":-1,"title":"BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)</title></head><body><p><span>Feb 6 (Reuters)</span><span> - </span>Priovant:</p><ul><li><p>PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)</p></li><li><p>PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li><li><p>PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA</p></li></ul><p>Source text: <span>ID:nGNX6Tw17l</span></p><p>Further company coverage: <span>ROIV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)</title></head><body><p><span>Feb 6 (Reuters)</span><span> - </span>Priovant:</p><ul><li><p>PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)</p></li><li><p>PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li><li><p>PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA</p></li></ul><p>Source text: <span>ID:nGNX6Tw17l</span></p><p>Further company coverage: <span>ROIV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA1GHWNM:1","article_id":"2609950605","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609950605","pubTimestamp":1770383476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)Feb 6 (Reuters) - Priovant:PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SAR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","ROIV":"Roivant Sciences Ltd."},"translate_title":"BRIEF-Priovant宣布Brepocitinib治疗皮肤结节病(Cs)的积极2期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":0.9},"content_text":"BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)Feb 6 (Reuters) - Priovant:PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTSPRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDASource text: ID:nGNX6Tw17lFurther company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609950605","isCrawlerRequest":true}